Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this internet live activity for a maximum of 17.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by November 27, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the AACR this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
The field of cellular metabolism and how it applies to the persistence and survival of cancer cells has expanded dramatically since the first description of metabolic discrepancies in cancer cells by Otto Warburg in 1956. Warburg observed that even in the presence of ample amounts of oxygen, cancer cells will metabolize glucose to produce ATP in the less-efficient process of glycolysis. Additionally, the processing and intake of nutrients are often dysregulated in growing cancer cells and can lead to cellular stress and local hypoxia in the tumor microenvironment. Furthermore, metabolism is affected when the most common cancer-associated mutations occur in the cell. The activation of many cancer-associated pathways, such as Ras or Myc, can promote glycolysis. The loss of tumor suppressor gene products, like p53, can interfere with aerobic respiration. Thus, the sum of metabolic changes involved cannot be captured by a single model and it is important to understand the basis and downstream effects of this heterogeneity in order to develop and optimize therapeutic strategies.
The basic biology of epigenetics and chromatin structure has laid the foundation for understanding how and when genes are expressed, i.e. “turned on or off.” We frequently see the normal process of the regulation of gene expression altered or mutated, resulting in the deregulation of genes or pathways, leading to cancer. In addition, tumor cells also use epigenetic processes to escape from chemotherapy and host immune surveillance.
There is a need to gather a range of basic/translational research scientists and clinicians to assess the result of altered cellular metabolism and its impact on the processes that contribute to epigenetic changes, and the proliferation and survival of cancer cells in the patient. Bridging the gap between what basic and translational scientists understand about cancer metabolism and epigenetics, and how physicians understand and apply this knowledge to clinical oncology is critical for the implementation of effective strategic approaches to aid in the diagnosis, treatment, and prevention of cancer. Furthermore, facilitating a dynamic interface between physicians and scientists at a conference targeted to both disciplines will increase knowledge of the current state of basic and translational research in the field of cancer metabolism and create a forum for discussion and collaboration to aid in the rapid translation of laboratory research findings to feasible “bench-to-bedside” treatment options based on the latest findings on metabolic pathways and cancer.
After participating in this CME activity, physicians should be able to:
- Articulate the role of metabolism in tumor progression and survival.
- Distinguish the different ways differentiation and metabolism are involved in tumorogenesis the impact on cell proliferation, cell survival, and cell death.
- Explain the interaction and relationship between epigenetics and tumor metabolism.
- Evaluate current approaches in stem cell maintenance and its association with metabolism.
- Identify approaches for exploring emerging concepts.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the website this conference.
Acknowledgment of Financial or Other Support
The AACR gratefully acknowledges the following commercial supporters:
PROFESSIONAL EDUCATIONAL GRANTS
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].